Oncopeptides AB (FRA:OND) Total Liabilities: €18.11 Mil (As of Mar. 2026)

What is Oncopeptides AB Total Liabilities?

Oncopeptides AB FRA:OND +5.66% 28 Total Liabilities is €18.11 Mil as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 28/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

Oncopeptides AB's Total Liabilities for the quarter that ended in Mar. 2026 was €18.11 Mil.

Oncopeptides AB's quarterly Total Liabilities declined from Sep. 2025 (€18.61 Mil) to Dec. 2025 (€17.85 Mil) but then increased from Dec. 2025 (€17.85 Mil) to Mar. 2026 (€18.11 Mil).

Oncopeptides AB's annual Total Liabilities increased from Dec. 2023 (€16.23 Mil) to Dec. 2024 (€16.51 Mil) and increased from Dec. 2024 (€16.51 Mil) to Dec. 2025 (€17.85 Mil).

Oncopeptides AB Total Liabilities Related Terms

Oncopeptides AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Total Liabilities Chart

Oncopeptides AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

22.25

8.28

16.23

16.51

17.85

Oncopeptides AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															16.36	18.46	18.61	17.85	18.11

28GF Score

Oncopeptides AB FRA:OND

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Oncopeptides AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Oncopeptides AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.141	+	(12.099	+	1.501
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.113	+	0)
	=	17.85

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	12.442	-	-5.412
	=	17.85

Oncopeptides AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.227	+	(12.143	+	0.743
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	18.11

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	25.242	-	7.129
	=	18.11

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of €18.11 Mil mean?

Oncopeptides AB (FRA:OND) has a Total Liabilities of €18.11 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oncopeptides AB and its competitors.

Is Oncopeptides AB's Total Liabilities too high?

Oncopeptides AB's current Total Liabilities is €18.11 Mil. Overall, Oncopeptides AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Oncopeptides AB's Total Liabilities compare to VRTX and REGN?

Oncopeptides AB's Total Liabilities of €18.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oncopeptides AB and its competitors. Oncopeptides AB's current Total Liabilities is €18.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Oncopeptides AB stock overvalued right now?

Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.15 — trading 60.6% below its estimated fair value. The current Total Liabilities is €18.11 Mil. Oncopeptides AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Total Liabilities is €18.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.15 is trading 60.6% below its estimated GF Value™ of €0.37. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

Total Liabilities: €18.11 Mil
GF Value™: €0.37 vs. price of €0.15 (60.6% below fair value)
GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:FLUO XSAT:CESSA OSTO:XSPRAY OSTO:CANTA OSTO:ALZCUR OSTO:SPRINT OSTO:CLBIO OSTO:IVACC OSTO:IBT B OSTO:ACE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges ONCO:Sweden ONCOs:UK 0RN4:UK

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37

Website https://www.oncopeptides.com

Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.

28GF Score

Get the complete analysis for FRA:OND

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15

Price

€0.37

GF Value

View FRA:OND Analysis

See Total Liabilities data for all stocks →